# Millions of New Yorkers consume cannabis; far fewer understand details, such as content … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/millions-of-new-yorkers-consume-cannabis-far-fewer-understand-details-such-as-content/ > **Published:** 2026-07-06T12:17:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-09T10:04:50-04:00 > **Clinical Summary:** UB study reveals cannabis label literacy gaps affecting THC/CBD dosing. Why consumer understanding matters for clinical safety. --- ✦ New CED Clinical Relevance #52 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchSafetyDosingPolicyTHCCBDIndustry Why This Matters Clinicians need to understand that patient [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may not correlate with their knowledge of product potency, cannabinoid content, or dosing information, which affects the clinician’s ability to assess actual exposure and counsel on risks. Low label comprehension in a large population suggests patients cannot reliably report what they are consuming, making clinical history-taking less reliable and potentially obscuring harmful drug interactions or dose-related adverse effects. Providers should actively educate patients about label information and standardized dosing rather than assuming users understand potency differences between products. Clinical Summary A University at Buffalo study of New York cannabis consumers found that despite millions of adults using cannabis products, the majority lack understanding of critical label information including potency, cannabinoid ratios, and product composition. This knowledge gap persists even in a regulated market with mandatory labeling requirements, suggesting that standardized labels may not effectively communicate essential safety and efficacy information to users. For clinicians, this disconnect between regulatory compliance and actual consumer comprehension represents a significant barrier to informed patient decision-making and safe use, particularly for patients managing chronic conditions or taking concurrent medications. Poor label comprehension may contribute to dosing errors, unexpected adverse effects, or suboptimal therapeutic outcomes when patients cannot accurately identify THC and CBD content or recognize product type differences. Healthcare providers should recognize that cannabis-using patients may not understand their products’ composition and should engage in detailed counseling about potency, onset time, and appropriate dosing rather than assuming label literacy. Clinicians are advised to directly discuss cannabis product specifics with patients and consider recommending standardized, simplified labeling formats that improve understanding and support safer, more effective therapeutic use. Dr. Caplan’s Take “This observational study from UB highlights a real gap between availability and informed use, though we should note it reflects self-reported awareness rather than measured comprehension or health outcomes. What concerns me clinically is that without understanding potency, cannabinoid profiles, and product type, patients can’t make decisions aligned with their individual risk factors or therapeutic goals, which undermines the whole premise of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) as a precision tool.” Clinical Perspective 💊 While [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) in New York has expanded access for millions of adults, this study highlights a critical gap between consumption patterns and label literacy that has direct clinical relevance. Patients may be unable to accurately report THC or CBD content, cannabinoid ratios, or potential contaminants when discussing their [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) during clinical encounters, complicating risk assessment and drug interaction screening. This knowledge deficit is particularly concerning given the wide variability in product potency across the legal market and the potential for cannabinoid-related adverse effects at higher doses. Clinicians should recognize that asking patients simply “do you use cannabis” may yield incomplete information, and consider more targeted questions about product type, frequency, and perceived effects rather than relying on patient understanding of labels. Given these limitations in patient awareness, healthcare providers should proactively educate patients about label information and standardized dosing concepts while acknowledging that comprehensive product knowledge cannot currently be assumed. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Millions%20of%20New%20Yorkers%20consume%20cannabis%3B%20far%20fewer%20understand%20details%2C%20such%20as%20content%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68400)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68400)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Millions%20of%20New%20Yorkers%20consume%20cannabis%3B%20far%20fewer%20understand%20details%2C%20such%20as%20content%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68400)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.wnypapers.com/news/article/current/2026/07/06/166483/millions-of-new-yorkers-consume-cannabis-far-fewer-understand-details-such-as-content-and-dosage](https://www.wnypapers.com/news/article/current/2026/07/06/166483/millions-of-new-yorkers-consume-cannabis-far-fewer-understand-details-such-as-content-and-dosage) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).